The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status

Cellular and Molecular Biology

Volumn 52, Issue 5, 2006, Pages 4-10

  Domagala T B ^a   Lacinski M ^b   Trzeciak, W H ^b   Mackness, B ^c   Mackness, M I ^c   Jakubowski, H ^a,d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

Age; Atherosclerosis; Genetic polymorphism; HDL; Homocysteine thiolactonase; LDL; Paraoxonase; Statins; Total cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE THIOLACTONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTOR VARIABLE; STENOSIS;

ADULT; AGED; ANIMALS; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; CORONARY DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; STATISTICS;

EID: 34247640295     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.1170/T727     Document Type: Article

References (40)

1. Voetsch, B., and Loscalzo, J., Genetic determinants of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24: 216-229.
2. Lusis, A.J., Atherosclerosis. Nature 2000, 407: 233-241.
3. Mackness, M., Durrington, P. and Mackness, B., Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr. Opin. Lipidol. 2004, 15: 399-404.
4. Shih, D.M., Gu, L., Xia, Y.R., Navab, M., Li, W.F., Hama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M. and Lusis, A.J., Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394: 284-287.
5. Tward, A., Xia, Y.R., Wang, X.P., Shi, Y.S., Park, C., Castellani, L.W., Lusis, A.J. and Shih, D.M., Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106: 484-490.
6. Jarvik, G.P., Rozek, L.S., Brophy, V.H., Hatsukami, T.S., Richter, R.J., Schellenberg, G.D. and Furlong, C.E., Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 2000, 20: 2441-2447.
7. Jarvik, G.P., Hatsukami, T.S., Carlson, C., Richter, R.J., Jampsa, R., Brophy, V.H., Margolin, S., Rieder, M., Nickerson, D., Schellenberg, G.D., Heagerty, P.J. and Furlong, C.E., Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23: 1465-1471.
8. Mackness, B., Davies, G.K., Turkie, W., Lee, E., Roberts, D.H., Hill, E., Roberts, C., Durrington, P.N. and Mackness, M.I., Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 2001, 21: 1451-1457.
9. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M. and Mackness, M.I., Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107: 2775-2779.
10. Wheeler, J.W., Keavney, B.D., Watkins, H., Collins, R. and Danesh, J., Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363: 689-695.
11. Marthe, G.K., Zimmerman, G.A. and McIntyre, T.M., Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 2003, 278: 3937-3947.
12. Teiber, J.F., Dragonov, D. and Maguire, G.F., Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J. Lipid Res. 2004, 45: 2260-2268.
13. Connelly, P.W., Draganov, D. and Maguire, G.F., Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic. Biol. Med. 2005, 38: 164-174.
14. Jakubowski, H., Molecular basis of homocysteine toxicity in humans. Cell. Mol. Life Sci. 2004, 61: 470-487.
15. Jakubowski, H., Calcium-dependent human serum homocysteine thiolactone hydrolase: A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 2000, 275: 3957-3962.
16. Jakubowski, H., Biosynthesis and reactions of homocysteine thiolactone. In Jacobson, D., Carmel, R., eds, Homocysteine in Health and Disease, Cambridge University Press, UK, 2001, pp 21-31.
17. Wald, D.S., Law, M. and Morris, J.K., Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med J. 2002, 325:1202-1209.
18. Jakubowski, H., Translational accuracy of aminoacyl-tRNA synthetases: Implications for atherosclerosis. J. Nutr. 2001, 131(suppl): 2983-2987.
19. Jakubowski, H., Editing of Errors in Amino Acid Selection for Protein Synthesis. In The Aminoacyl-tRNA Synthetases (Ibba, M., Francklyn, C., Cusack, S. (eds.), Landes Bioscience, Georgetown, TX, 2005, pp.384-396.
20. Jakubowski, H., Metabolism of homocysteine thiolactone in human cell cultures: Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 1997, 272: 1935-1941.
21. Jakubowski, H., Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999, 13: 2277-2283.
22. Jakubowski, H., Homocysteine is a protein amino acid in humans: Implications for homocysteine-linked disease. J. Biol. Chem. 2002, 277: 30425-30428.
23. Undas, A., Perła, J., Łaciński, M., Trzeciak, W.H., Kaźmierski, R. and Jakubowski, H., Autoantibodies against N-homocysteinylated proteins in humans: Implications for atherosclerosis. Stroke 2004, 35: 1299-1304.
24. Undas, A., Jankowski, M., Twardowska, M., Padjas, A., Jakubowski, H. and Szczeklik, A., Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005, 93: 346-350.
25. Lentz, S.R., Mechanisms of homocysteine-induced atherothrombosis. J. Thromb. Haemost. 2005, 3: 1646-1654.
26. Roybal, C.N., Yang, S., Sun, C.W., Hurtado, D., Vander Jagt D.L., Townes, T.M. and Abcouwer, S.F., Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J. Biol. Chem. 2004, 279: 14844-14852.
27. Mercie, P., Garnier, O., Lascoste, L., Renard, M., Closse, C., Durrieu, F., Marit, G., Boisseau, R.M. and Belloc, F., Homocysteine thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis 2000, 5: 403-411
28. Jakubowski, H., Ambrosius, W. and Pratt, J.H., Genetic determinants of homocysteine thiolactonase activity in humans: Implications for atherosclerosis. FEBS Lett.2001, 491: 35-39.
29. Jakubowski, H., Zhang, L., Bardeguez, A. and Aviv, A., Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: Implications for atherosclerosis. Circ. Res. 2000, 87: 45-51.
30. Łaciński, M., Skorupski, W., Cieśliński, A., Sokołowska, J., Trzeciak, W.H. and Jakubowski, H., Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell. Mol. Biol. 2004, 50: 885-893.
31. Jakubowski, H., The determination of homocysteinethiolactone in biological samples. Anal. Biochem. 2002, 308: 112-119.
32. Chwatko, G. and Jakubowski, H., The determination of homocysteine- thiolactone in human plasma. Anal. Biochem. 2005, 337: 271-277.
33. Chwatko, G. and Jakubowski, H., Urinary excretion of homocysteine- thiolactone in humans. Clin. Chem. 2005, 51: 408-415.
34. Khersonsky, O. and Tawfik, D.S., Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44: 6371-6382.
35. Mackness, M,I., Durrington, P.N. and Mackness, B., The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am. J. Cardiovasc. Drugs 2004, 4: 211-217.
36. Gouedard, C., Koum-Besson, N., Barouki, R. and Morel, Y., Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 2003, 63: 945-956.
37. Deakin, S., Leviev, I., Guernier, S. and James, R.W., Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 2003, 23: 2083-2089.
38. Beltowski, J., Wojcicka, G., Jamroz, A., Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J. Cardiovasc. Pharmacol. 2004, 43: 121-127.
39. Tomas, M., Senti, M., Garcia-Faria, F., Vila, J., Torrents, A., Covas, M. and Marrugat, J., Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20: 2113-2119.
40. Rozek, L.S., Hatsukami, T.S., Richter, R.J., Ranchalis, J., Nakayama, K., McKinstry, L.A., Gortner, D.A., Boyko, E., Schellenberg, G.D., Furlong, C.E. and Jarvik, G.P., The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J. Lipid Res. 2005, 46: 1888-95.